Agonist antibodies that bind human CD137 and uses thereof

US11752207B2 · kind B2 · utility

Assignee

• Compass Therapeutics LLC · US

Inventors

• Piotr Bobrowicz · Lebanon, US
• Paul Fredrick Widboom · Lebanon, US
• Michael March Schmidt · Cambridge, US
• Jason M. Lajoie · Cambridge, US
• Robert V. Tighe, III · North Reading, US
• Cheuk Lun Leung · Cambridge, US
• Ugur Eskiocak · Cambridge, US

Key dates

• Filing date: Jun 8, 2020
• Grant date: Sep 12, 2023
• Expiry date: Oct 7, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/75
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.